Molecular Pharmacology (USA) Ltd. engages in the development of pharmaceutical products. The company is headquartered in Leederville, Western Australia. The company went IPO on 2005-05-20. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The firm and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.
Follow-Up Questions
Qui est le CEO de Molecular Pharmacology (USA) Ltd ?
Jeffery Edwards est le President de Molecular Pharmacology (USA) Ltd, il a rejoint l'entreprise depuis 2005.
Quelle est la performance du prix de l'action MLPH ?
Le prix actuel de MLPH est de $0.0004, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Molecular Pharmacology (USA) Ltd ?
Molecular Pharmacology (USA) Ltd appartient à l'industrie N/A et le secteur est N/A
Quelle est la capitalisation boursière de Molecular Pharmacology (USA) Ltd ?
La capitalisation boursière actuelle de Molecular Pharmacology (USA) Ltd est de $399.8K
